Biocon gets tentative approval from USFDA for Dasatinib tablets

07 Feb 2024 Evaluate

Biocon has received tentative approval of its ANDA for Dasatinib tablets from the USFDA, for strengths of 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg. This product is indicated for use in the treatment of Philadelphia chromosome positive chronic myeloid leukemia in adults. 

It is also used to treat Philadelphia chromosome positive acute lymphoblastic leukemia in adults with resistance or intolerance to prior therapy. The approval will further strengthen Biocon’s portfolio of vertically integrated, complex drug products.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.


Biocon Share Price

307.00 15.30 (5.25%)
26-Apr-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1504.25
Dr. Reddys Lab 6263.70
Cipla 1406.25
Zydus Lifesciences 948.20
Lupin 1615.85
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.